What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?

What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?

What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor James CH Yang, MD, PhD

Professor James CH Yang, MD, PhD

Professor, Graduate Institute of Oncology
National Taiwan University
Director, Department of Oncology
National Taiwan University Hospital
Taipei, Taiwan